These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 35157644)

  • 1. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
    Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
    Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
    Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
    JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Fennema H; Spiessens B; Offergeld K; Scheper G; Taylor KL; Robb ML; Treanor J; Barouch DH; Stoddard J; Ryser MF; Marovich MA; Neuzil KM; Corey L; Cauwenberghs N; Tanner T; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2021 Jun; 384(23):2187-2201. PubMed ID: 33882225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
    van der Neut Kolfschoten M; Inganäs H; Perez-Peinado C; Calado da Silva Freire J; Melchers JM; van Dijk N; Przeradzka M; Kourkouta E; van Manen D; Vellinga J; Custers J; Bos R
    J Thromb Haemost; 2024 Apr; 22(4):1046-1055. PubMed ID: 38159648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
    Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
    Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
    Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
    Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
    Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
    Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S
    Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
    Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M
    Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.
    Morehouse ZP; Paulus A; Jasti SA; Bing X
    Cureus; 2021 Sep; 13(9):e18153. PubMed ID: 34703690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
    Lewis NM; Self WH; Gaglani M; Ginde AA; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Ghamande SA; McNeal TA; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Busse LW; Lohuis CCT; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Lauring AS; Halasa N; Chappell JD; Grijalva CG; Rice TW; Rhoads JP; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Adams K; Patel MM; Tenforde MW;
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S159-S166. PubMed ID: 35675695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome.
    Li HF; Hu SM; Lv M
    JAMA; 2022 Jan; 327(4):392-393. PubMed ID: 35076675
    [No Abstract]   [Full Text] [Related]  

  • 18. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
    Kitchin D; Richardson SI; van der Mescht MA; Motlou T; Mzindle N; Moyo-Gwete T; Makhado Z; Ayres F; Manamela NP; Spencer H; Lambson B; Oosthuysen B; Kaldine H; du Pisanie M; Mennen M; Skelem S; Williams N; Ntusi NAB; Burgers WA; Gray GG; Bekker LG; Boswell MT; Rossouw TM; Ueckermann V; Moore PL
    Cell Rep Med; 2022 Mar; 3(3):100535. PubMed ID: 35474744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK
    Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study.
    Morciano C; Spila Alegiani S; Menniti Ippolito F; Belleudi V; Trifirò G; Zanoni G; Puccini A; Sapigni E; Mores N; Leoni O; Monaco G; Clagnan E; Zappetti C; Bovo E; Cutillo M; Da Cas R; Massari M
    PLoS One; 2024; 19(1):e0290879. PubMed ID: 38241309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.